Major Histocompatibility Complex class II antigen-processing and presentation machinery (MHCII-APP)

The Major Histocompatibility Complex (MHC) class II antigen-processing and presentation machinery is a specialized system in professional antigen-presenting cells, such as dendritic cells and B cells, that displays exogenous peptides to CD4+ T cells (Roche & Furuta, 2015, Nature Reviews Immunology). This machinery comprises MHC II heterodimers (HLA-DR, -DQ, -DP), the invariant chain (CD74), and chaperones like HLA-DM that facilitate peptide loading (Uniprot, 2024). The pathway is critical for the initiation of adaptive immune responses and the maintenance of peripheral tolerance. Dysregulation of this system is a hallmark of autoimmune diseases, where self-antigens are erroneously presented, and oncology, where tumors downregulate these components to evade the immune system (Axelrod et al., 2019, JCI Insight). Therapeutic targeting of this machinery involves inhibiting proteases like Cathepsin S to block antigen loading or using monoclonal antibodies against CD74 to treat hematological malignancies (Gupta et al., 2019, Blood).

Other names

MHC class II pathwayExogenous antigen presentation pathwayHLA class II processing machineryMHCII-APPM

The machinery is targeted through several distinct mechanisms: inhibition of cysteine proteases like Cathepsin S to prevent the degradation of the invariant chain (CD74) and subsequent peptide loading (Roche & Furuta, 2015, Nature Reviews Immunology); direct binding of monoclonal antibodies to CD74 to induce cell death in malignant B cells (Gupta et al., 2019, Blood); and the use of peptide-based therapies to competitively occupy the MHC II binding groove to induce T-cell anergy in autoimmune contexts (Holoshitz, 2010, Journal of Autoimmunity).